Cell and Gene Therapy
Opportunities and challenges of precision medicine in Europe
Cell, gene and other emerging therapies are distinctly different from traditional one-size-fits-all medicinal products. How can life sciences companies address challenges along key stages of the product life cycle?
Distribution and Supply Chain Models in the Cell & Gene Therapy Landscape
The pandemic has forced the adoption of new ways of working and a re-architected work model. Discover how we can help organisations work toward the new normal.
Cell and Gene therapies (CGT), including personalized medicines have rapidly transformed the curative treatment landscape.
2021 global life sciences outlook
Possibility is now reality, sustaining forward momentum
Navigating the pandemic has been an all-encompassing, once-in-a-lifetime challenge. Globally, life sciences companies responded with leadership and are emerging stronger. How will life sciences companies continue to respond and what areas can they build resiliency going forward?
Early value assessments for Biotech companies
Optimise the upside value potential of your asset to advance investor’s interest
We provide Biotech start-ups with the required expertise and experience to evaluate the upside potential value of their assets to advance investor’s interest.
The future unmasked
Predicting the future of healthcare and life sciences in 2025
What does the future hold for the life sciences and healthcare industry? Our latest predictions report looks ahead to the year 2025 to help you see what’s coming and to keep your organisation moving forward.
Time to care
Securing a future for the hospital workforce in Europe
In light of rising demand, staff shortages and lack of time for hands-on-care, is the current hospital workforce model sustainable? New research released by the Deloitte UK Centre for Health Solutions explores the current state of hospital workforces across Europe and their key challenges.